98%
921
2 minutes
20
Purpose: We compared the negative chronotropic and inotropic effects of landiolol and esmolol, two clinically available short-acting beta1-blockers with high beta1-selectivity, using whole isolated rabbit heart preparations.
Methods: Tachycardia was induced by continuous perfusion of 10(-7) M isoproterenol, and we used concentrations of landiolol or esmolol in ascending steps (1 . 10(-6), 3 . 10(-6), 1 . 10(-5), 3 . 10(-5), and 1 x 10(-4) M). Heart rate (HR), left ventricular developed pressure (LVDP), the maximal rates of left ventricular force development (LVdP/dt(max)), and myocardial oxygen consumption (MVO2) were measured and compared.
Results: Both landiolol and esmolol produced dosedependent decreases in HR, LVDP, LVdP/dt(max), and MVO2. The HR lowering effects of the two agents were comparable. At concentrations of 3 . 10(-5) and 1 . 10(-4) M, esmolol produced more profound depression of LVDP (47 +/- 26 and 12 +/- 11 mmHg, respectively; mean +/- SD) and reduction of LVdP/dt(max) (650 +/- 287 and 120 +/- 103 mmHg x s(-1)) than landiolol (68 +/- 20 and 64 +/- 20 mmHg, and 897 +/- 236 and 852 +/- 240 mmHg.s(-1), respectively). At the same concentrations, esmolol caused more profound reduction in MVO(2) (40 +/- 11 and 35 +/- 10 microl x min(-1) x g(-1)) than landiolol (50 +/- 8 and 48 +/- 8 microl x min(-1) x g(-1)), respectively.
Conclusion: Our results indicate that in the isolated rabbit heart, landiolol and esmolol had equipotent negative chronotropic effects, however, landiolol had a less potent negative inotropic effect than esmolol.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00540-008-0640-4 | DOI Listing |
Cureus
July 2025
Cardiology, Hospital Sirio-Libanes, São Paulo, BRA.
Landiolol is being investigated for its potential to manage septic shock (SS) and sepsis-related tachyarrhythmias (TA). We performed a systematic review and meta-analysis of three randomized controlled trials (RCTs) involving 473 patients with sepsis or SS, including those with TA, comparing landiolol to standard therapy-controlled (STC) groups. Standard therapy consisted of usual sepsis care ± placebo but excluded β-blockers in the control arms.
View Article and Find Full Text PDFCardiol Rev
July 2025
Department of Nursing, Westchester Medical Center, Valhalla, NY.
In 2025, the Food and Drug Administration approved landiolol (Rapiblyk), an intravenous β1-adrenoreceptor blocker for the rapid and short-term reduction of the ventricular rate in adult patients with supraventricular tachycardia, which includes those patients with atrial fibrillation and flutter. Other intravenous β-blockers approved for the same indication include esmolol (Brevibloc) and generics, and propranolol generics. Intravenous metoprolol (generic) is used off-label.
View Article and Find Full Text PDFCard Fail Rev
May 2025
ICU Department, University Hospital, Democritus University of Thrace Alexandroupolis, Greece.
Background: Weaning and tracheal extubation of patients after vascular surgery is a stressful procedure that triggers the sympathetic nervous system, potentially leading to deterioration of cardiac performance in patients with left ventricular dysfunction. This study compared the efficacy and safety of landiolol, a novel ultra-short-acting β-adrenoceptor antagonist, with that of esmolol in terms of the cardiovascular response during the extubation of patients with reduced ejection fraction (EF) admitted to the intensive care unit after major vascular surgery.
Methods: This single-centre, prospective, randomised, open-label study included postoperative patients with cardiac dysfunction.
Crit Care Med
May 2025
Department of Medicine, The Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA.